Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The dynamic roles of the bladder tumour microenvironment
Yu‐Cheng Lee, Hung‐Ming Lam, Charles J. Rosser, et al.
Nature Reviews Urology (2022) Vol. 19, Iss. 9, pp. 515-533
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy
Boda Guo, Feiya Yang, Lingpu Zhang, et al.
Advanced Materials (2023) Vol. 35, Iss. 22
Closed Access | Times Cited: 207
Bladder cancer
Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 144
Circulating tumor cells: from new biological insights to clinical practice
Xuyu Gu, Shiyou Wei, Xin Lv
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 17
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer
Tianlei Xie, Shan Peng, Shujun Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method
Qiushi Feng, Xiaofeng Shan, Vicky Yau, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 62-62
Open Access | Times Cited: 1
Identification of endothelial-related molecular subtypes for bladder cancer patients
Dengxiong Li, Dechao Feng, Xu Shi, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 23
Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy
Fenggang Qi, Qunqun Bao, Ping Hu, et al.
Biomaterials (2024) Vol. 307, pp. 122514-122514
Closed Access | Times Cited: 11
Current advances in modulating tumor hypoxia for enhanced therapeutic efficacy
Zihan Liu, Xinping Liu, Wei Zhang, et al.
Acta Biomaterialia (2024) Vol. 176, pp. 1-27
Open Access | Times Cited: 7
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
S. Evans, Yash Jani, Caroline S. Jansen, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect
Conghua Lu, Ziyuan Gao, Di Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009165-e009165
Open Access | Times Cited: 7
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
Fotis Nikolos, Kazukuni Hayashi, Xen Ping Hoi, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 30
TGF-β1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells
Qinrong Ping, Chunhui Wang, Xin Cheng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 18
Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer
Omar M. Ibrahim, Paweł Kaliński
Cells (2024) Vol. 13, Iss. 8, pp. 699-699
Open Access | Times Cited: 5
Identification and multi-dimensional validation of mitochondrial permeability transition-driven necrosis-related model to assess the prognosis and immunotherapy value in breast cancer
Jinsong Liu, Wei Tong, Liuliu Quan, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy
Xingjie Hu, Ni‐Yuan Zhang, Da‐Yong Hou, et al.
Advanced Materials (2023) Vol. 35, Iss. 45
Closed Access | Times Cited: 12
Patient‐derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T‐cell Recognition**
Zihan Zhao, Shuren Zhang, Ning Jiang, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 9
Closed Access | Times Cited: 4
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer
Qing-xin Yu, Jiaochen Wang, Jun-fei Liu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production
Enguang Yang, Suoshi Jing, Fang Wang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 9
Open Access | Times Cited: 3
Patient‐derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T‐cell Recognition**
Zihan Zhao, Shuren Zhang, Ning Jiang, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 9
Closed Access | Times Cited: 2
Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment
Zihan Xu, Yujie Zhao, Yong Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification
Mitchell Olislagers, Florus C. de Jong, Vera C Rutten, et al.
Nature Reviews Urology (2024)
Closed Access | Times Cited: 2
Radiomics for the Prediction of Overall Survival in Patients with Bladder Cancer Prior to Radical Cystectomy
Piotr Woźnicki, Fabian Christopher Laqua, Katharina Messmer, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4449-4449
Open Access | Times Cited: 12
METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS
Jie-Xun Chen, Dongming Chen, Dong Wang, et al.
Oncology Reports (2023) Vol. 49, Iss. 5
Open Access | Times Cited: 6
The Future of Antibody–Drug Conjugates in Urothelial Cancer
David Alex Goodson, Terence W. Friedlander
Advances in Oncology (2023) Vol. 3, Iss. 1, pp. 137-159
Open Access | Times Cited: 5
Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer
Daniel Ruben Akiola Sanya, Djamila Onésime
Human Cell (2023) Vol. 36, Iss. 4, pp. 1343-1372
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top